Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Polynovo ( (AU:PNV) ) is now available.
PolyNovo has appointed Dr Marthe D’Ombrain as Chief Scientific Officer, effective 1 June 2026, strengthening its leadership team as it advances its NovoSorb technology platform for complex wound care. Dr D’Ombrain brings more than two decades of experience in R&D strategy, external innovation, licensing and commercialisation, most recently as Executive Director and Head of Global Research Innovation at CSL, and holds governance roles including a non-executive directorship at AusBiotech.
The company expects her expertise in building global research portfolios, forging academic and industry partnerships, and navigating listed-company governance to accelerate pipeline development and support PolyNovo’s next phase of growth. CEO Bruce Peatey highlighted that her track record in translating scientific innovation into growth programs will be instrumental in scaling NovoSorb products globally, while D’Ombrain said she aims to use her global networks and innovation experience to increase the velocity of PolyNovo’s R&D pipeline and bolster its expanding international footprint.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$1.80 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo Limited is a Melbourne-based medical technology company focused on transforming the management of complex wounds through its proprietary NovoSorb biodegradable polymer platform. The company markets products such as NovoSorb BTM, a synthetic dermal scaffold, and NovoSorb MTX, a fully synthetic dermal matrix cleared by the U.S. FDA, and has established international operations across the United States, United Kingdom, India, Hong Kong, Singapore and other distributor-supported markets. Achievements including sustained revenue growth, profitability, multiple regulatory clearances and market leadership in several geographies underpin PolyNovo’s strategy to leverage its technology platform into new products and markets.
Average Trading Volume: 2,665,093
Technical Sentiment Signal: Sell
Current Market Cap: A$708.1M
Find detailed analytics on PNV stock on TipRanks’ Stock Analysis page.